Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFTR microbiome analysis after Orkambi initiation in cystic fibrosis
NL-OMON23453Recruiting
- Sponsor
- University of Amsterdam
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of lumacaftor + ivacaftor in cystic fibrosis (CF), sponsored by University of Amsterdam. Primary endpoints: Bacterial sequences, Metabolic profiles and 1 more. Started Nov 2017; status: recruiting.
02
Drugs
lumacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON23453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23453.